BioCentury
ARTICLE | Company News

Amgen, Novartis biosimilars news

May 11, 2015 7:00 AM UTC

The U.S. Court of Appeals for the Federal Circuit (CAFC) granted Amgen’s motion for a preliminary injunction against Novartis’ Sandoz Inc. generics unit to delay the launch of Zarxio filgrastim-sndz, a biosimilar of Amgen’s Neupogen filgrastim, until the court resolves Amgen’s appeal. Amgen argued that it would suffer irreparable harm from price erosion upon Zarxio’s launch. The CAFC did not provide a reason for its decision. ...